CYTK
Price
$36.81
Change
+$0.22 (+0.60%)
Updated
Jul 11, 11:30 AM (EDT)
Capitalization
4.37B
20 days until earnings call
INMB
Price
$2.23
Change
-$0.13 (-5.51%)
Updated
Jul 10 closing price
Capitalization
64.29M
19 days until earnings call
Interact to see
Advertisement

CYTK vs INMB

Header iconCYTK vs INMB Comparison
Open Charts CYTK vs INMBBanner chart's image
Cytokinetics
Price$36.81
Change+$0.22 (+0.60%)
Volume$300
Capitalization4.37B
INmune Bio
Price$2.23
Change-$0.13 (-5.51%)
Volume$1.9M
Capitalization64.29M
CYTK vs INMB Comparison Chart in %
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. INMB commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a StrongBuy and INMB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (CYTK: $36.59 vs. INMB: $2.23)
Brand notoriety: CYTK and INMB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 70% vs. INMB: 58%
Market capitalization -- CYTK: $4.37B vs. INMB: $64.29M
CYTK [@Biotechnology] is valued at $4.37B. INMB’s [@Biotechnology] market capitalization is $64.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileINMB’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • INMB’s FA Score: 0 green, 5 red.
According to our system of comparison, CYTK is a better buy in the long-term than INMB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 5 TA indicator(s) are bullish while INMB’s TA Score has 5 bullish TA indicator(s).

  • CYTK’s TA Score: 5 bullish, 3 bearish.
  • INMB’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than INMB.

Price Growth

CYTK (@Biotechnology) experienced а +5.57% price change this week, while INMB (@Biotechnology) price change was -11.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10.37%. For the same industry, the average monthly price growth was +18.17%, and the average quarterly price growth was +23.18%.

Reported Earning Dates

CYTK is expected to report earnings on Oct 30, 2025.

INMB is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+10.37% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($4.37B) has a higher market cap than INMB($64.3M). CYTK YTD gains are higher at: -22.215 vs. INMB (-52.248). INMB has higher annual earnings (EBITDA): -41.52M vs. CYTK (-513.62M). CYTK has more cash in the bank: 938M vs. INMB (19.3M). INMB has less debt than CYTK: INMB (347K) vs CYTK (791M). CYTK has higher revenues than INMB: CYTK (19.2M) vs INMB (50K).
CYTKINMBCYTK / INMB
Capitalization4.37B64.3M6,802%
EBITDA-513.62M-41.52M1,237%
Gain YTD-22.215-52.24843%
P/E RatioN/AN/A-
Revenue19.2M50K38,400%
Total Cash938M19.3M4,860%
Total Debt791M347K227,954%
FUNDAMENTALS RATINGS
CYTK vs INMB: Fundamental Ratings
CYTK
INMB
OUTLOOK RATING
1..100
1650
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
81100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
6298
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INMB's Valuation (79) in the Biotechnology industry is in the same range as CYTK (100). This means that INMB’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (81) in the Biotechnology industry is in the same range as INMB (100). This means that CYTK’s stock grew similarly to INMB’s over the last 12 months.

INMB's SMR Rating (99) in the Biotechnology industry is in the same range as CYTK (100). This means that INMB’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Price Growth Rating (62) in the Biotechnology industry is somewhat better than the same rating for INMB (98). This means that CYTK’s stock grew somewhat faster than INMB’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for INMB (100). This means that CYTK’s stock grew significantly faster than INMB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKINMB
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 9 days ago
83%
Declines
ODDS (%)
Bearish Trend 12 days ago
78%
Bearish Trend 11 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HRCAX116.92N/A
N/A
Harbor Capital Appreciation Admin
ALVSX10.71N/A
N/A
American Century Focused Lg Cap Val I
RYCHX169.61N/A
N/A
Rydex Technology C
CISMX13.34N/A
N/A
Clarkston Partners Institutional
WGMVX4.28N/A
N/A
Wasatch Micro Cap Value Institutional